ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.
The Philips Azurion interventional imaging system was recently updated with new ultralow dose technology that is said to reduce X-ray exposure by up to 50% during coronary procedures.
Researchers tracked data from nearly 400 women with complex CAD who underwent treatment with Shockwave Medical's intravascular lithotripsy technology prior to PCI.
Even seeing a cardiologist once per year can help these patients elevate their long-term survival. Many stay home, however, missing out on potentially life-saving guidance and/or treatment.
Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.
There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes.
Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis.
Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview.
